FR15C0056I1 - - Google Patents

Info

Publication number
FR15C0056I1
FR15C0056I1 FR15C0056C FR15C0056I1 FR 15C0056 I1 FR15C0056 I1 FR 15C0056I1 FR 15C0056 C FR15C0056 C FR 15C0056C FR 15C0056 I1 FR15C0056 I1 FR 15C0056I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27668840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0056(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR15C0056I1 publication Critical patent/FR15C0056I1/fr
Application granted granted Critical
Publication of FR15C0056I2 publication Critical patent/FR15C0056I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
FR15C0056C 2001-10-11 2015-08-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS Active FR15C0056I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32810101P 2001-10-11 2001-10-11
US40693402P 2002-08-30 2002-08-30
EP02804818.9A EP1442047B1 (en) 2001-10-11 2002-10-11 Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Publications (2)

Publication Number Publication Date
FR15C0056I1 true FR15C0056I1 (en) 2015-09-11
FR15C0056I2 FR15C0056I2 (en) 2016-06-03

Family

ID=27668840

Family Applications (4)

Application Number Title Priority Date Filing Date
FR15C0056C Active FR15C0056I2 (en) 2001-10-11 2015-08-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS
FR17C1042C Active FR17C1042I2 (en) 2001-10-11 2017-11-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS
FR17C1043C Active FR17C1043I2 (en) 2001-10-11 2017-11-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS
FR17C1044C Active FR17C1044I2 (en) 2001-10-11 2017-11-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS

Family Applications After (3)

Application Number Title Priority Date Filing Date
FR17C1042C Active FR17C1042I2 (en) 2001-10-11 2017-11-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS
FR17C1043C Active FR17C1043I2 (en) 2001-10-11 2017-11-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS
FR17C1044C Active FR17C1044I2 (en) 2001-10-11 2017-11-10 NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL MENINGITIS

Country Status (19)

Country Link
US (13) US8101194B2 (en)
EP (14) EP2366707B1 (en)
JP (6) JP2005515771A (en)
KR (4) KR101068318B1 (en)
CN (4) CN102755631B (en)
AU (3) AU2009213040C1 (en)
BE (3) BE2017C057I2 (en)
BR (1) BRPI0212999B8 (en)
CA (5) CA2918207C (en)
DK (10) DK2348036T3 (en)
ES (14) ES2561430T3 (en)
FR (4) FR15C0056I2 (en)
HK (2) HK1178429A1 (en)
IL (5) IL161052A0 (en)
LU (4) LU92786I2 (en)
MX (3) MX339524B (en)
NL (3) NL300899I2 (en)
PT (10) PT2348035E (en)
WO (1) WO2003063766A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261346A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
CA2373236C (en) 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
CA2954411A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
DK1897555T3 (en) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Supplemental OMV vaccine against meningococcus
DK1947187T5 (en) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid expression of neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
US20070253964A1 (en) * 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc Multivalent pneumococcal polysacharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
PT1896065E (en) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AU2013201318B2 (en) * 2005-11-25 2015-11-19 Glaxosmithkline Biologicals Sa Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CN101535493A (en) 2006-07-27 2009-09-16 惠氏公司 High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (en) * 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
BRPI0923006A2 (en) 2008-12-17 2016-03-08 Novartis Ag meningococcal vaccines including hemoglobin receptor
EP2411045A1 (en) * 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
DK2411048T3 (en) 2009-03-24 2020-06-15 Glaxosmithkline Biologicals Sa ADJUSTIVE MENINGOCOC FACTOR H BINDING PROTEIN
ES2596653T3 (en) 2009-06-16 2017-01-11 Glaxosmithkline Biologicals Sa Opsonization bactericidal and antibody-dependent assays mediated by high-performance complement
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
WO2011024071A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
ES2661569T3 (en) * 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland H-factor binding proteins (fHbp) with altered properties and methods of use thereof
EP3170508B1 (en) 2010-06-04 2019-11-13 Wyeth LLC Vaccine formulations
CA2803239A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
AU2011294776B2 (en) * 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
KR20140026392A (en) 2011-03-02 2014-03-05 노파르티스 아게 Combination vaccines with lower doses of antigen and/or adjuvant
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
US9657297B2 (en) 2012-02-02 2017-05-23 Glaxosmithkline Biologicals Sa Promoters for increased protein expression in meningococcus
EP2823312B1 (en) 2012-03-08 2019-08-07 GlaxoSmithKline Biologicals SA In vitro potency assay for protein-based meningococcal vaccines
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP4043029A1 (en) * 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RU2644340C2 (en) 2012-06-14 2018-02-08 Новартис Аг Vaccines for serogroup x meningococcus
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
ES2685894T3 (en) 2013-03-08 2018-10-15 Pfizer Inc. Immunogenic fusion polypeptides
AU2014296027A1 (en) 2013-08-02 2016-02-04 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
MX369534B (en) 2013-09-08 2019-11-11 Pfizer Neisseria meningitidis compositions and methods thereof.
US10392424B2 (en) 2014-02-28 2019-08-27 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
CR20170020A (en) 2014-07-23 2017-08-10 Children´S Hospital & Res Center At Oakland VARIANTS OF PROTEIN UNIONS TO FACTOR H AND METHODS OF USE OF THESE
WO2016081314A1 (en) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
EP3263695A1 (en) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
CN106434720A (en) * 2016-08-03 2017-02-22 中国医学科学院医学生物学研究所 Method for improving expression of neisseria meningitidis fHBP
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
MX2019009011A (en) 2017-01-31 2019-09-26 Pfizer Neisseria meningitidis compositions and methods thereof.
WO2019065555A1 (en) 2017-09-28 2019-04-04 富士フイルム株式会社 Image capturing device, information acquisition method and information acquisition program
JP6856762B2 (en) * 2017-09-28 2021-04-14 富士フイルム株式会社 Imaging device, information acquisition method and information acquisition program
TWI687696B (en) * 2019-06-26 2020-03-11 國立中興大學 Method for establishing feedback type hidden Markov model identifier and method for establishing identification system based on the identifier
CN114681601A (en) * 2020-12-31 2022-07-01 基础治疗有限公司 Neisseria meningitidis vaccines and uses thereof
AU2022223712A1 (en) 2021-02-19 2023-10-05 Sanofi Pasteur Inc. Meningococcal b recombinant vaccine
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
WO2023138914A1 (en) 2022-01-24 2023-07-27 Koninklijke Philips N.V. Pulse wave velocity determination using co-registration between intravascular data and extraluminal image, and associated systems, devices, and methods
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (en) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 Adjuvanted immunogenic composition against neisseria meningitidis b

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT280356B (en) 1968-03-06 1970-04-10 Telefonbau & Normalzeit Gmbh Circuit arrangement for controlling the capacitor of a demodulator of a time division multiplex system used for the intermediate storage of the time value of a signal
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CH660375A5 (en) * 1983-02-08 1987-04-15 Sclavo Spa PROCEDURE FOR THE PRODUCTION OF PROPHINES RELATED TO DIPHTERIC TOXIN.
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4668829A (en) * 1984-07-18 1987-05-26 University Patents, Inc. Ferroelectric smectic liquid crystals
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
SE8405493D0 (en) * 1984-11-01 1984-11-01 Bror Morein IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS
FR2573436B1 (en) 1984-11-20 1989-02-17 Pasteur Institut RECOMBINANT DNA COMPRISING A NUCLEOTIDE SEQUENCE ENCODING A DETERMINED POLYPEPTIDE UNDER THE CONTROL OF AN ADENOVIRUS PROMOTER, VECTORS CONTAINING THIS RECOMBINANT DNA, EUKARYOT CELLS TRANSFORMED BY THIS RECOMBINANT DNA, THE CONSTITUTION OF VACCINES
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JPH01125328A (en) 1987-07-30 1989-05-17 Centro Natl De Biopreparados Meningococcus vaccine
JPH01144977A (en) 1987-11-30 1989-06-07 Agency Of Ind Science & Technol Novel recombinant plasmid ptpgif2
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990002806A1 (en) 1988-09-01 1990-03-22 Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
ATE110965T1 (en) 1989-03-09 1994-09-15 Praxis Biolog Inc VACCINES AGAINST HEMOPHILUS INFLUENCAE.
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
JPH0453645U (en) * 1990-09-12 1992-05-07
EP0550553B1 (en) 1990-09-25 2000-07-12 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993007897A1 (en) 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
IT1253009B (en) 1991-12-31 1995-07-10 Sclavo Ricerca S R L DETOXIFIED IMMUNOGENIC MUTANTS OF COLERIC TOXIN AND TOXIN LT, THEIR PREPARATION AND USE FOR THE PREPARATION OF VACCINES
WO1993015115A1 (en) * 1992-01-24 1993-08-05 Cornell Research Foundation, Inc. E. coli dna polymerase iii holoenzyme and subunits
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
DE69434079T2 (en) * 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid for the production of CRM protein and diphtheria toxin
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
DK0624376T3 (en) 1993-05-13 2000-07-24 American Cyanamid Co Preparation and use of LOS-depleted outer membrane proteins of gram-negative cocci
FR2705361B1 (en) 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
RU2219241C2 (en) 1993-07-13 2003-12-20 Рон-Пуленк Роре С.А. Defective recombinant adenoviral vector (variants)
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
EP0711354A1 (en) 1993-07-30 1996-05-15 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
US5550213A (en) * 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
FR2714830B1 (en) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
FR2715847B1 (en) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition containing nucleic acids, preparation and uses.
FI98045C (en) 1994-02-21 1997-04-10 Arto Remes Device for incontinence treatment
FR2716459B1 (en) 1994-02-22 1996-05-10 Univ Paris Curie Host-vector system usable in gene therapy.
WO1995026411A2 (en) 1994-03-25 1995-10-05 The Uab Research Foundation Composition and methods for creating syngeneic recombinant virus-producing cells
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
ATE173634T1 (en) * 1994-04-20 1998-12-15 Us Army VACCINE AGAINST GRAM-NEGATIVE BACTERIAL INFECTIONS
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
FR2727679B1 (en) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa NEW TRANSFECTION AGENTS AND THEIR PHARMACEUTICAL APPLICATIONS
BE1008978A5 (en) 1994-12-27 1996-10-01 Solvay Adjuvants for vaccines.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (en) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur Proteinase k resistant surface protein of neisseria meningitidis
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
PT832093E (en) * 1995-06-07 2006-12-29 Sanofi Pasteur Inc Expression of lipoproteins
FR2741358B1 (en) 1995-11-17 1998-01-02 Centre Nat Rech Scient PRODUCTION OF RETROVIRAL VECTORS VIA DNA VIRUS-BASED VIRAL VECTORS
CU22559A1 (en) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech EXPRESSION SYSTEM OF HETEROLOGICAL ANTIGENS IN E. COLI AS FUSION PROTEINS
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
WO1998008874A1 (en) 1996-08-27 1998-03-05 Chiron Corporation Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions
WO1998008543A1 (en) 1996-08-27 1998-03-05 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE19723095C2 (en) * 1997-06-02 2001-08-23 Siemens Ag Image reconstruction method for a computer tomograph
JP4664450B2 (en) 1997-06-30 2011-04-06 アンステイテユ・ギユスタブ・ルシー Improved methods for introducing nucleic acids into multicellular eukaryotic cells and combinations thereof
WO1999001175A1 (en) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
DE69826124T3 (en) 1997-06-30 2007-10-11 Institut Gustave Roussy ADMINISTRATION OF NUCLEIC ACID IN CROSS-LINKED MUSCLES
JP2001510169A (en) * 1997-07-17 2001-07-31 ノース アメリカン ワクチン， インコーポレイテッド Meningococcal type B porin and H. Immunogenic conjugates comprising influenzae polysaccharides
JPH1144977A (en) 1997-07-25 1999-02-16 Copyer Co Ltd Image forming device
ATE421527T1 (en) 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic MOLECULAR MIMETICS OF MENINGOCOCCUS B EPITOPES
AU753943B2 (en) * 1997-08-29 2002-10-31 Dow Global Technologies Inc. Homogeneous filled polymer composite
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PT1047784E (en) 1998-01-14 2009-12-21 Novartis Vaccines & Diagnostic Neissera meningitidis antigens
US7635486B1 (en) * 1998-02-03 2009-12-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant lipidated PsaA protein, methods of preparation and use
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261346A3 (en) * 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
JP5074644B2 (en) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Combination meningococcal B / C vaccine
WO2000018355A2 (en) * 1998-09-30 2000-04-06 Walter Reed Army Institute Of Research Use of purified invaplex from gram negative bacteria as a vaccine
IL142231A0 (en) 1998-09-30 2002-03-10 American Cyanamid Co Mutant cholera holotoxin as an adjuvant
MXPA01003557A (en) 1998-10-09 2004-04-05 Chiron Corp Neisseria genomic sequences and methods of their use.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6281337B1 (en) 1998-11-12 2001-08-28 Schering Corporation Methods for conversion of protein isoforms
JP2004537954A (en) 1999-01-15 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Neisseria meningitidis polypeptide BASB052
CA2360658A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) * 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
SI1150712T1 (en) 1999-02-05 2009-02-28 Merck & Co Inc Human papilloma virus vaccine formulations
CA2371994C (en) 1999-02-26 2010-09-28 Guido Grandi Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
EP2278007B1 (en) 1999-04-30 2014-04-16 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
CN1359426A (en) 1999-04-30 2002-07-17 希龙公司 Neisseria genomic sequences and methods of their use
CA2373236C (en) * 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
CA2954411A1 (en) 1999-10-29 2001-05-03 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1741784T3 (en) 1999-11-29 2010-05-25 Novartis Vaccines & Diagnostic 85kDa antigen from neisseria
ES2307553T3 (en) 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. COMPOSITIONS AND PROCEDURES TO STABILIZE BIOLOGICAL MOLECULES AFTER LIOPHILIZATION.
DK1897555T3 (en) 2000-01-17 2014-10-13 Novartis Vaccines & Diagnostic Supplemental OMV vaccine against meningococcus
DK1947187T5 (en) * 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid expression of neisserial proteins
SK287689B6 (en) 2000-06-08 2011-06-06 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410635B (en) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh VACCINE COMPOSITION
HU230490B1 (en) 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
EP1373314A2 (en) 2001-03-30 2004-01-02 Geneprot, Inc. Human arginine-rich protein-related compositions
AU2002258734A1 (en) 2001-04-13 2002-10-28 Wyeth Holdings Corporation Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography
AU2002252638A1 (en) 2001-04-17 2002-10-28 Children's Hospital Oakland Research Institute Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE451386T1 (en) 2001-06-07 2009-12-15 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANTS
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN100350972C (en) 2001-07-26 2007-11-28 启龙股份公司 Vaccines comprising aluminium adjuvants and histidine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US20070020622A1 (en) * 2001-09-14 2007-01-25 Invitrogen Corporation DNA Polymerases and mutants thereof
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0129007D0 (en) 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
DE60325565D1 (en) 2002-03-26 2009-02-12 Novartis Vaccines & Diagnostic MODIFIED SACCHARIDES WITH IMPROVED STABILITY IN WATER
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
BR0310042A (en) 2002-05-14 2005-04-05 Chiron Srl Mucosal combination vaccines for bacterial meningitis
DE60328481D1 (en) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic SLEEP-CAPACITIVE VACCINE CONTAINING THE ADJUVANZ CHITOSAN AND MENIGOKOKKENANTIGENE
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
ATE466875T1 (en) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic UNEXPECTED SURFACE PROTEINS IN NEISSERIA MENINGITIDIS
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP1590459A2 (en) * 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
CA2514328C (en) 2003-01-30 2020-01-14 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
US20070253964A1 (en) 2003-04-16 2007-11-01 Zlotnick Gary W Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease
US9107831B2 (en) 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
WO2005000345A2 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1670506B1 (en) 2003-10-02 2012-11-21 Novartis AG Liquid vaccines for multiple meningococcal serogroups
CN1901935A (en) 2003-12-30 2007-01-24 惠氏公司 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP1740217B1 (en) 2004-04-30 2011-06-15 Novartis Vaccines and Diagnostics S.r.l. Meningococcal conjugate vaccination
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
WO2006011060A2 (en) 2004-07-23 2006-02-02 Chiron Srl Polypeptides for oligomeric assembly of antigens
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419846D0 (en) 2004-09-07 2004-10-13 Chiron Srl Vaccine adjuvants for saccharides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
AU2006208208B2 (en) 2005-01-27 2011-05-19 Children's Hospital & Research Center At Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
WO2006096701A2 (en) 2005-03-07 2006-09-14 Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America Pharmaceutical liposomal compositions
EP1885734B1 (en) 2005-05-06 2015-01-14 Novartis AG Immunogens for meningitidis-a vaccines
PT1896065E (en) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
EP1967204B1 (en) 2005-09-01 2013-10-30 Novartis Vaccines and Diagnostics GmbH Multiple vaccination including serogroup c meningococcus
US8679770B2 (en) 2005-09-05 2014-03-25 Glaxo Smith Kline Biologicals S.A. Serum bactericidal assay for N. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EA200801368A1 (en) 2005-12-23 2008-12-30 Глаксосмитклайн Байолоджикалс С.А. CONJUGATE VACCINES
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2044104A2 (en) * 2006-06-29 2009-04-08 Novartis AG Polypeptides from neisseria meningitidis
CN101535493A (en) 2006-07-27 2009-09-16 惠氏公司 High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2688268A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20090035328A1 (en) * 2007-08-02 2009-02-05 Dan Granoff fHbp- AND LPXL1-BASED VESICLE VACCINES FOR BROAD SPECTRUM PROTECTION AGAINST DISEASES CAUSED BY NEISSERIA MENINGITIDIS
PL2200642T3 (en) 2007-10-19 2012-09-28 Novartis Ag Meningococcal vaccine formulations
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
MX2010008799A (en) 2008-03-05 2010-09-07 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition.
CA2717870A1 (en) * 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
US20100035234A1 (en) 2008-05-19 2010-02-11 Novartis Ag Vaccine assays
NZ589812A (en) 2008-05-30 2012-08-31 U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
WO2010027872A1 (en) 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Complement factor h-based assays for serum bactericidal activity against neisseria meningitidis
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
IT1394288B1 (en) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic PROTEIN IMMUNOGENES THAT LINK THE FACTOR H.
CN104740631B (en) 2008-10-29 2019-04-16 阿布林克斯公司 The preparation of single domain antigen-binding molecule
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
JP5410084B2 (en) * 2008-12-15 2014-02-05 川上産業株式会社 Packing box and box-shaped core
BRPI0923006A2 (en) 2008-12-17 2016-03-08 Novartis Ag meningococcal vaccines including hemoglobin receptor
EP2411045A1 (en) 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
DK2411048T3 (en) 2009-03-24 2020-06-15 Glaxosmithkline Biologicals Sa ADJUSTIVE MENINGOCOC FACTOR H BINDING PROTEIN
BRPI1013902A2 (en) 2009-04-30 2019-09-24 Children´S Hospital & Res Center At Oakland chimeric factor binding protein h (fhbp) is method of use
US9365885B2 (en) 2009-06-16 2016-06-14 Puiying Annie Mak High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
CA2776004A1 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
JP3158225U (en) * 2009-10-22 2010-03-25 王　文燦 Folding storage bag
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
ES2707778T3 (en) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Immunogens polysaccharides conjugated with carrier proteins of E. coli
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012022688A2 (en) 2010-03-10 2018-05-22 Glaxosmithkline Biologicals Sa fusion protein, isolated outer membrane vesicle, polynucleotide, pharmaceutical composition, vaccine, method for treating or preventing neisseria infection or disease, use and method for making a fusion protein
BR112012022896A2 (en) 2010-03-18 2018-03-27 Novartis Ag adjuvant vaccines for serogroup b meningococci
ES2661569T3 (en) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland H-factor binding proteins (fHbp) with altered properties and methods of use thereof
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
ES2744471T3 (en) 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Bactericidal antibody assays to assess immunogenesis and potency of meningococcal capsular saccharide vaccines
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
US20120070457A1 (en) 2010-09-10 2012-03-22 J. Craig Venter Institute, Inc. Polypeptides from neisseria meningitidis
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
KR20140026392A (en) 2011-03-02 2014-03-05 노파르티스 아게 Combination vaccines with lower doses of antigen and/or adjuvant
US9181308B2 (en) 2011-03-28 2015-11-10 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2685894T3 (en) 2013-03-08 2018-10-15 Pfizer Inc. Immunogenic fusion polypeptides
US9965924B2 (en) 2013-07-15 2018-05-08 Ahmnon D. Moskowitz Methods, systems, and apparatus for playing multi-zone 21
MX369534B (en) 2013-09-08 2019-11-11 Pfizer Neisseria meningitidis compositions and methods thereof.
RU2723045C2 (en) 2015-02-19 2020-06-08 Пфайзер Инк. Compositions of neisseria meningitidis and methods for preparation thereof
MX2019009011A (en) 2017-01-31 2019-09-26 Pfizer Neisseria meningitidis compositions and methods thereof.

Also Published As

Publication number Publication date
CA2463476A1 (en) 2003-08-07
JP2017025061A (en) 2017-02-02
CA2918207C (en) 2016-10-18
NL300897I1 (en) 2017-10-20
US9623101B2 (en) 2017-04-18
FR17C1043I1 (en) 2017-12-22
FR17C1044I2 (en) 2018-12-07
JP5976880B2 (en) 2016-08-24
DK2348035T3 (en) 2015-04-20
WO2003063766A2 (en) 2003-08-07
EP2348036A2 (en) 2011-07-27
EP2348034B1 (en) 2016-11-02
PT2341062T (en) 2017-06-02
US20110076299A1 (en) 2011-03-31
BR0212999A (en) 2006-05-23
AU2009213040C1 (en) 2012-10-11
DK2343308T3 (en) 2015-03-30
ES2532640T3 (en) 2015-03-30
US20190151431A1 (en) 2019-05-23
US20120201844A1 (en) 2012-08-09
CA2918207A1 (en) 2003-08-07
BE2017C055I2 (en) 2022-02-01
EP2351767B1 (en) 2015-08-26
JP2015214545A (en) 2015-12-03
AU2009213040A1 (en) 2009-10-08
EP2332961A3 (en) 2011-07-27
US20120308595A1 (en) 2012-12-06
DK2371838T3 (en) 2016-02-22
ES2625876T3 (en) 2017-07-20
AU2012202916A1 (en) 2012-06-07
US8563006B2 (en) 2013-10-22
PT2351767E (en) 2015-10-30
EP2341063A2 (en) 2011-07-06
EP2341062A2 (en) 2011-07-06
CN102836426A (en) 2012-12-26
FR17C1044I1 (en) 2017-12-22
EP2341062B1 (en) 2017-03-29
EP2348036A3 (en) 2011-08-03
NL300897I2 (en) 2018-04-06
US20120294880A1 (en) 2012-11-22
JP5923070B2 (en) 2016-05-24
US9757444B2 (en) 2017-09-12
DK2348036T3 (en) 2016-02-22
JP5404441B2 (en) 2014-01-29
KR101068318B1 (en) 2011-09-28
KR101215664B1 (en) 2012-12-26
HK1178429A1 (en) 2013-09-13
IL233545A (en) 2017-10-31
ES2562811T3 (en) 2016-03-08
KR20100121699A (en) 2010-11-18
CA2894296A1 (en) 2003-08-07
NL300896I2 (en) 2018-04-06
BRPI0212999B8 (en) 2021-07-27
CN102755631A (en) 2012-10-31
LUC00041I2 (en) 2017-12-20
KR20100028657A (en) 2010-03-12
EP1442047B1 (en) 2016-03-16
EP2371838B1 (en) 2015-12-16
DK2341063T3 (en) 2015-10-26
ES2781213T3 (en) 2020-08-31
ES2603531T3 (en) 2017-02-28
MX339524B (en) 2016-05-30
US20150335724A1 (en) 2015-11-26
US20200138933A1 (en) 2020-05-07
EP1442047A2 (en) 2004-08-04
EP2341063B1 (en) 2015-08-26
MXPA04003356A (en) 2004-11-29
NL300896I1 (en) 2017-10-20
LUC00040I1 (en) 2017-10-16
US10300122B2 (en) 2019-05-28
FR15C0056I2 (en) 2016-06-03
KR20110117726A (en) 2011-10-27
EP2332961A2 (en) 2011-06-15
EP2341063A3 (en) 2011-09-14
ES2568895T3 (en) 2016-05-05
PT2371838E (en) 2016-03-23
EP2332961B1 (en) 2016-07-27
EP2341062A3 (en) 2011-09-14
CA2939781A1 (en) 2003-08-07
PT3199539T (en) 2020-04-01
IL161052A0 (en) 2004-08-31
IL245955B (en) 2018-01-31
EP2348034A2 (en) 2011-07-27
DK3199539T3 (en) 2020-04-27
AU2018203627A1 (en) 2018-06-07
US9132182B2 (en) 2015-09-15
US9168293B2 (en) 2015-10-27
LU92786I2 (en) 2015-11-02
US8563007B1 (en) 2013-10-22
US20150216960A1 (en) 2015-08-06
EP3199539B1 (en) 2020-03-11
AU2012202916B2 (en) 2013-08-01
EP2371837A1 (en) 2011-10-05
BE2017C056I2 (en) 2022-02-01
PT2371836T (en) 2017-02-17
EP2351767A2 (en) 2011-08-03
EP2348035B1 (en) 2015-02-18
ES2549764T3 (en) 2015-11-02
PT2343308E (en) 2015-03-25
KR101099916B1 (en) 2011-12-28
NL300899I1 (en) 2017-10-20
US20130259889A1 (en) 2013-10-03
IL245956B (en) 2019-02-28
EP2371836A1 (en) 2011-10-05
LUC00041I1 (en) 2017-10-16
FR17C1042I1 (en) 2017-12-22
IL161052A (en) 2015-04-30
CN102836426B (en) 2016-09-28
BE2017C057I2 (en) 2022-02-01
CA2894296C (en) 2018-05-01
JP5997400B2 (en) 2016-09-28
ES2615206T3 (en) 2017-06-05
EP2348034A3 (en) 2011-09-21
DK2341062T3 (en) 2017-05-08
CN1578785B (en) 2013-03-13
EP2371838A1 (en) 2011-10-05
DK2332961T3 (en) 2016-10-03
EP2371837B1 (en) 2016-09-21
US9107873B2 (en) 2015-08-18
EP2366707B1 (en) 2016-09-21
EP3199539A1 (en) 2017-08-02
FR17C1043I2 (en) 2018-12-07
PT2348035E (en) 2015-03-25
PT2341063E (en) 2015-10-29
US20170173140A1 (en) 2017-06-22
KR20040066793A (en) 2004-07-27
HK1178800A1 (en) 2013-09-19
CN105617372A (en) 2016-06-01
WO2003063766A3 (en) 2004-01-08
US20060257413A1 (en) 2006-11-16
NL300899I2 (en) 2018-04-06
BRPI0212999B1 (en) 2020-04-28
JP2014012002A (en) 2014-01-23
EP2343308B1 (en) 2015-02-18
PT2332961T (en) 2016-09-28
ES2593360T3 (en) 2016-12-07
EP2348035A2 (en) 2011-07-27
US11116829B2 (en) 2021-09-14
EP2348035A3 (en) 2011-09-14
DK2371836T3 (en) 2017-02-20
CA2849427C (en) 2016-10-04
ES2532639T3 (en) 2015-03-30
CN1578785A (en) 2005-02-09
ES2609039T3 (en) 2017-04-18
PT2348036E (en) 2016-03-09
JP2016165275A (en) 2016-09-15
US20120034261A1 (en) 2012-02-09
EP2343308A2 (en) 2011-07-13
EP2366707A1 (en) 2011-09-21
CN102755631B (en) 2015-11-25
EP1442047A4 (en) 2005-06-01
ES2561430T3 (en) 2016-02-26
JP2005515771A (en) 2005-06-02
IL233545A0 (en) 2014-08-31
US8101194B2 (en) 2012-01-24
MX349481B (en) 2017-07-31
DK2351767T3 (en) 2015-10-26
ES2549765T3 (en) 2015-11-02
CA2463476C (en) 2017-09-12
AU2009213040B2 (en) 2012-03-01
CA2939781C (en) 2022-09-13
CA2849427A1 (en) 2003-08-07
LUC00042I1 (en) 2017-10-16
US20120301496A1 (en) 2012-11-29
EP2343308A3 (en) 2011-07-27
EP2351767A3 (en) 2011-09-14
AU2012202916C1 (en) 2017-06-08
LUC00042I2 (en) 2017-12-20
FR17C1042I2 (en) 2018-12-07
ES2603532T3 (en) 2017-02-28
LUC00040I2 (en) 2017-12-20
IL245955A0 (en) 2016-07-31
EP2371836B1 (en) 2016-12-14
JP2010162023A (en) 2010-07-29
EP2348036B1 (en) 2015-12-16
IL245956A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
BE2022C547I2 (en)
BE2017C051I2 (en)
BE2017C032I2 (en)
BE2016C051I2 (en)
BE2017C050I2 (en)
BE2014C004I2 (en)
BE2014C006I2 (en)
BE2012C050I2 (en)
BE2012C022I2 (en)
BE2011C034I2 (en)
BE2007C047I2 (en)
AU2002307149A8 (en)
JP2002231904A5 (en)
JP2002054091A5 (en)
BRPI0209186B1 (en)
JP2002061600A5 (en)
BE2016C021I2 (en)
BE2014C008I2 (en)
BRPI0204884A2 (en)
CH1379220H1 (en)
JP2002162205A5 (en)
JP2002098931A5 (en)
BE2012C051I2 (en)
JP2001255394A5 (en)
BRPI0210463A2 (en)